Wnt Signaling Modulation represents a promising therapeutic approach for neurodegenerative diseases that targets the highly conserved Wnt/β-catenin signaling pathway. This pathway plays crucial roles in neuronal development, synaptic plasticity, and cellular homeostasis. Dysregulation of Wnt signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1].
The Wnt signaling pathway is a critical evolutionary conserved system that regulates cell fate, proliferation, and differentiation during development and adult tissue homeostasis. In the central nervous system, Wnt signaling governs:
In neurodegenerative diseases, Wnt signaling becomes dysregulated, leading to impaired neurogenesis, synaptic dysfunction, and increased neuronal vulnerability[2]. Therapeutic modulation of this pathway aims to restore normal signaling and protect against neurodegeneration.
The canonical Wnt/β-catenin pathway involves the following key components:
Wnt ligand + Frizzled + LRP5/6 → Dishevelled activation → β-catenin stabilization → Nuclear translocation → Target gene transcription
In addition to the canonical pathway, non-canonical Wnt signaling (including Wnt/planar cell polarity and Wnt/Ca²⁺ pathways) also plays important roles in neuronal function[3].
Wnt modulators can be classified by their mechanism:
| Mechanism | Compound | Action |
|---|---|---|
| GSK-3β inhibition | Lithium, CHIR99021 | Stabilize β-catenin |
| Wnt ligand secretion | IWP-2, IWP-4 | Porcupine inhibitors |
| Frizzled receptor modulation | OMP-54F28 | FZD8-Fc fusion protein |
| Wnt replacement | Wnt7a | Recombinant protein |
In AD models, Wnt signaling modulation has shown promising effects:
Amyloid Pathology:
Tau Pathology:
Neuroprotection:
In PD models, Wnt modulation has demonstrated neuroprotective effects:
In ALS models, Wnt signaling shows complex interactions:
CHIR99021 is a selective GSK-3β inhibitor that activates Wnt signaling:
Lithium is a well-known mood stabilizer with GSK-3β inhibitory activity:
Wnt7a is a recombinant Wnt ligand:
IWP-2 is a porcupine inhibitor that blocks Wnt secretion:
| Trial ID | Compound | Condition | Phase | Status |
|---|---|---|---|---|
| NCT04564144 | Lithium | AD | Phase II | Recruiting |
| NCT04286529 | Lithium | PD | Phase II | Completed |
| NCT03889470 | Lithium | ALS | Phase II | Completed |
Multiple clinical trials are investigating lithium repurposing for neurodegenerative diseases:
Several Wnt-targeted approaches are in various stages of development:
Wnt modulation therapy requires careful consideration of risks:
Oncological Risks:
Developmental Risks:
Lithium:
CHIR99021:
Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and Alzheimer's disease. J Mol Neurosci. 2014. ↩︎
Palomer E, Buee L, Sergeant N, et al. Wnt/β-catenin signaling in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2016. ↩︎
Barraud-Libersa C, Vasquez C, Chen M, et al. Non-canonical Wnt signaling in neuronal development and function. Dev Neurobiol. 2018. ↩︎
Tapia-Rojas C, Schuller A, Inestrosa NC. Lithium as a candidate drug for Alzheimer's disease. Int Rev Neurobiol. 2020. ↩︎
Group J, Avila J, Lucas JJ. Inhibition of GSK-3 as a therapeutic strategy for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2018. ↩︎